Ir para o conteúdo principal

Recce Pharmaceuticals (ASX: RCE) — Perfil da empresa, notícias e dados financeiros

Logo de Recce Pharmaceuticals
RCE Recce Pharmaceuticals
Recce Pharmaceuticals primary media
Perfil da empresa

Recce Pharmaceuticals

Recce Pharmaceuticals is a biotechnology company developing a new class of synthetic anti-infectives to address antibiotic-resistant superbugs and viral pathogens. The company's lead synthetic polymer compounds are engineered to maintain potency without inducing cellular resistance, offering potential treatments for life-threatening microbial infections. Recce Pharmaceuticals advances multiple clinical development programs, including intravenous formulations for systemic conditions such as sepsis and urosepsis, and topical applications for acute bacterial skin infections, burn wounds, and diabetic foot ulcers. The company conducts clinical trials across Australia and international jurisdictions while operating specialized manufacturing capabilities to supply synthetic candidates for ongoing regulatory trials.

Resumo

Public AUParticipação acionária
2007Ano de fundação
11–50Funcionários
Sydney, AustraliaSede
Carregando mapa...
Presença global

Operações

Todos os locais
Sydney, AU
Australia

Produtos e/ou serviços de Recce Pharmaceuticals

  • Intravenous Anti-Infective Therapy: Formulation administered via intravenous infusion targeting serious systemic infections, including sepsis and urosepsis, currently undergoing Phase 2 clinical trials across clinical sites in Australia to evaluate safety, efficacy, and dosage profiles.
  • Topical Burn Wound Anti-Infective: Gel-based synthetic polymer formulation developed for topical application to treat acute bacterial skin and skin structure infections, including burn wound infections, undergoing clinical evaluation in Australian hospital centers.
  • Diabetic Foot Infection Anti-Infective: Topical synthetic compound designed for treating complicated diabetic foot ulcers and associated bacterial infections, evaluated in registrational clinical trials in Indonesia and Australia to address multidrug-resistant pathogens.
  • Urinary Tract Infection Therapeutics: Systemic anti-infective program evaluating intravenous delivery for complicated urinary tract infections, targeting acute and recurrent uropathogenic bacterial strains resistant to conventional antibiotic treatments in Phase 2 clinical trials.
  • Anti-Viral Synthetic Candidates: Pre-clinical and early-stage development program evaluating synthetic polymer compounds against viral pathogens, focusing on broad-spectrum anti-viral activity and universal mechanisms of action against rapidly mutating viral pathogen strains.
  • Automated Manufacturing Operations: In-house clinical manufacturing facility located in Macquarie Park, Sydney, Australia, supporting automated pilot-scale batch production, quality testing, and supply of synthetic anti-infective formulations for ongoing clinical trials.

equipe executiva do Recce Pharmaceuticals

  • John K. A. PrendergastExecutive Chairman of the Board
  • James Hamilton-Bray GrahamCEO, MD & Executive Director
  • Michele Keryn DiliziaChief Scientific Officer & Executive Director
  • Justin WardHead of Chemistry, Principal Quality Chemist & Executive Director
  • Arthur KollarasPrincipal Engineer & Head of Manufacturing
  • Alan W. DuntonChief Medical Advisor & Non Executive Director
  • Justin ReynoldsChief Financial Officer
  • Daniel AstudilloHead of Marketing
  • Maggie NiewidokCompany Secretary

Comunicados recentes

O que a Recce Pharmaceuticals (RCE) comunicou ao mercado, do mais recente para o mais antigo.

  1. Cleansing Notice
  2. Application for quotation of securities - RCE
  3. Notification regarding unquoted securities - RCE
  4. Final Director's Interest Notice - Mr McKeough
  5. Results of Meeting
  6. AGM Presentation
  7. Retirement of Mr Alistair McKeough as Non-Executive Director
  8. Options Prospectus

Principais indicadores financeiros

Resultados divulgados pela Recce Pharmaceuticals, em AUD.

Cap. de mercado
114,7 mi
Receita (TTM)
9,5 mi
P/L
—
LPA (diluído, TTM)
-0.1
Dividend yield
—
Margem de lucro
-158.1%
Receita e lucro anuais da Recce Pharmaceuticals
Fim do ano fiscalReceitaResultado operacionalLucro líquido
—-23,2 mi-15 mi
7,5 mi-22,9 mi-21,4 mi
5 mi-22,1 mi-17,7 mi
4,4 mi-17,3 mi-13,1 mi